 |
January-December 2004 Volume 1 | Issue 1
Page Nos. 5-255
Accessed 261,127 times.
PDF access policy Journal allows immediate open access to content in HTML + PDF
EPub access policy Full text in EPub is free except for the current issue. Access to the latest issue is reserved only for the paid subscribers.
|
| |
|
Show all abstracts Show selected abstracts Add to my list |
|
FOREWORD |
|
|
 |
Foreword |
p. 5 |
Baruch S Blumberg |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
EDITORIAL |
 |
|
|
|
Editorial |
p. 7 |
Shivaram Prasad Singh, Yogesh Kumar Chawla |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
REVIEW ARTICLE |
 |
|
|
|
From Australia antigen to eradication programs |
p. 10 |
Baruch S Blumberg |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Epidemiology of hepatitis B virus infection in India |
p. 17 |
Abhijit Chowdhury |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Prophylaxis of viral hepatitis: A global perspective |
p. 25 |
Voranush Chongsrisawat, Pantipa Chatchatee, Yong Poovorawan |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Universal neonatal hepatitis B virus vaccination in India: Why? |
p. 60 |
Rakesh Aggarwal |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Hepatitis B virus infection in children in India |
p. 72 |
Malathi Sathiyasekaran, VS Sankaranarayanan |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Histopathological scoring of chronic viral hepatitis |
p. 92 |
Gupta S Datta |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
 |
Management of chronic hepatitis due to hepatitis B virus infection |
p. 113 |
Subrat Kumar Acharya, Yogesh Batra |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Hepatitis B associated hepatocellular carcinoma: Epidemiology, diagnosis and treatment |
p. 140 |
KM Mohandas |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Management of HBV infection in decompensated liver disease |
p. 153 |
Sudeep Khanna, Arun Kumar |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Hepatitis B virus infection in pregnancy |
p. 199 |
Narendra Prasad Bohidar |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Approach to the management of an incidentally detected HBsAg carrier |
p. 210 |
Yogesh Kumar Chawla |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Treatment of chronic hepatitis B in HIV patients |
p. 217 |
Gourdas Choudhuri Infection with HIV and HBV often coexist in the same patient as the two viruses share similar modes of transmission. Around 10% of HIV patients are co-infected with HBV. With early diagnosis of HIV infection and effective anti-retroviral treatment leading to improved survival of patients with HIV infection, Hepatitis B related liver disease is emerging as a significant health problem in this group of patients.
Acute Hepatitis B tends to become chronic more often in HIV patients (80% vs 10% in HIV uninfected) indicating an immune dysfunction and defective clearance of the virus. Protection against HBV infection should be provided to HIV patients by effective use of Hepatitis B vaccine. Higher and frequent doses may be required in HIV patients as their immune response rates are poor.
The response to treatment of CHB with Interferon-alpha in HIV patients is around 0-10%, much less than what is achieved in non-HIV patients. Considering the cost, adverse effects and the poor response with Interferon-alpha, there is lack of optimism vis-a-vis its use in HIV patients.
The nucleoside analogue, Lamivudine, has shown promise in this group of patients. Lamivudine is useful in suppressing replication of both HIV and HBV. It has been found to be effective in suppressing HBV replication in 96% of HIV patients with chronic Hepatitis B infection. This was associated with clinical, biochemical and histological improvement in liver function. The dose of Lamivudine required in this special group is higher (300 mg/day), and the duration of treatment is long (until HBe sero-conversion and disappearance of HBV-DNA from blood). Besides, rebound viral replication on discontinuation of treatment and the development of YMDD mutants while on prolonged treatment are major concerns at the moment. |
[ABSTRACT] [HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
HBV and Indian medical and dental students  |
p. 229 |
Shivaram Prasad Singh, Manorama Swain, Indu Bhusan Kar |
[HTML Full text] [PDF] [Comments (1)] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Hepatitis B Immunization: FAQs  |
p. 240 |
Shivaram Prasad Singh |
[HTML Full text] [PDF] [Comments (1)] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Comments on the prevention of hepatitis B infection in India |
p. 249 |
Baruch S Blumberg |
[HTML Full text] [PDF] [Sword Plugin for Repository]Beta |
|
|
|
|
|